This site is intended only for healthcare professionals resident in Thailand

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

AboutAboutMDDVMSTreatmentTreatmentMDDVMSPUBLICATIONS & FAQsPUBLICATIONS & FAQsPUBLICATIONSFAQsSupporting ResourcesSupporting ResourcesEventsMaterialsVideos
Episode 1

In patients with AF and ACS/PCI, why is it important to focus on all 3 components - preventing stent thrombosis & ischemic events, and managing bleeding risks?

 See videoLoadingEpisode 1

In terms of background therapy, what was different in AUGUSTUS, compared with RE-DUAL and PIONEER?
 

 See videoLoadingEpisode 1

Do you foresee the results of AUGUSTUS changing the guideline recommendations?


 

 See videoLoadingEpisode 1

Can the results of AUGUSTUS be extrapolated to other NOACs?
 

 See videoLoadingEpisode 1

There is a trend toward the use of low-dose NOACs in Asian patients to reduce the risk of bleeding. What are the concerns regarding this practice?

 See videoLoading
Episode 2

What can we learn from AUGUSTUS that is not already known from RE-DUAL and PIONEER?
 

 See videoLoadingEpisode 2

What are your thoughts about the dosing of NOACs used in PIONEER, RE-DUAL and AUGUSTUS?
 

 See videoLoadingEpisode 2

Based on the AUGUSTUS results, what would be the role of aspirin as part of the recommended care with P2Y12 inhibitor and a NOAC to reduce ischemic risk for patients with AF and ACS/PCI?

 See videoLoadingEpisode 2

In clinical practice, apixaban is frequently prescribed at lower than the recommended dose. In what circumstances would this be warranted?

 See videoLoading
Episode 4

How is the population studied in AUGUSTUS different from those studied in RE-DUAL and PIONEER?
 

 See videoLoadingEpisode 4

Why was the 14-day prerandomization and a 6-month follow-up period chosen for the AUGUSTUS study?
 

 See videoLoadingEpisode 4

Would you change the patient who is on VKA therapy plus a P2Y12 inhibitor to receive a NOAC instead of VKA?
 

 See videoLoadingEpisode 4

What are your comments on the population in the AUGUSTUS trial that received a lower apixaban dose?
 

 See videoLoading
PP-ELI-THA-0631

Adverse events should be reported. Reporting forms and information can be found at https://www.pfizersafetyreporting.com/#/en

 

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This website is intended only for healthcare professionals registered in Thailand. If you are a non-registered healthcare professional in Thailand wishing to access general health and medical information, please visit [www.pfizer.co.th].

This website is brought to you by Pfizer (Thailand) Limited. 
 
You are now leaving the PfizerPro Thailand website
 ​
You are being directed to a third-party website. Please note that this third-party website is not controlled by PfizerPro Thailand or subject to our privacy policy. Thank you for visiting our site. We hope your visit was informative and enjoyable.
PP-UNP-THA-0485​
You are now leaving the PfizerPro Thailand website You are being directed to a third-party website. Please note that this third-party website is not controlled by PfizerPro Thailand or subject to our privacy policy. Thank you for visiting our site. We hope your visit was informative and enjoyable.